Abstract

Severe asthma in children is considered a complex and heterogeneous disease. A multidisciplinary assessment is required to correctly identify and manage these children because they potentially need close monitoring and additional treatment with advanced targeted therapies. Recent research efforts focused on the identification of epidemiologic, clinical, and functional characteristics of the disease in the pediatric age. Novel findings on the molecular mechanisms underlying severe asthma have led to the recognition of different endotypes and related biomarkers able to predict the response to advanced biologic therapies. Progress in our knowledge of severe asthma has occurred with the introduction of biologic therapies. Future goals in asthma care include the identification of the links between phenotypes and endotypes, as well as the identification of novel predictive biomarkers. They will help to select candidates for innovative biologic therapies and ultimately improve outcomes in children with severe asthma.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call